| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16754 R70382 |
Vajda a (Oxcarbazepine) (Controls exposed to LTG) (Epilepsy), 2024 | Intra uterine foetal death (including both spontaneous abortions and stillbirths, but not elective termination) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.43 [0.29;20.44] C excluded (control group) |
1/14 10/326 | 11 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16202 R67132 |
Vajda a (Oxcarbazepine) (Controls unexposed sick) (Epilepsy), 2024 | Intra uterine foetal death (including both spontaneous abortions and stillbirths, but not elective termination) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 35.64 [1.38;921.29] C | 1/14 0/149 | 1 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9078 R31076 |
Trivedi (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.08 [0.27;4.27] C excluded (control group) |
5/56 4/48 | 9 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9079 R31077 |
Trivedi (Oxcarbazepine) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 7.53 [1.54;36.89] | 5/56 5/178 | 10 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9077 R31074 |
Tomson (Oxcarbazepine), 2015 | Intrauterine death | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.08 [0.67;1.72] C | 22/262 150/1,910 | 172 | 262 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 4.29 [0.62;29.59] | 183 | 332 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Oxcarbazepine) (Controls unexposed sick) (Epilepsy; 2: Oxcarbazepine) (Controls unexposed, sick; 3: Oxcarbazepine;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9078, 16754